Aspen Pharmacare Holdings Limited
Aspen Pharmacare Holdings Limited
Your view on APNHY
Overview
What the company does, where it operates, and who runs it.
About Aspen Pharmacare Holdings Limited
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Stephen Bradley Saad
- Headquarters
- Aspen Place, Durban, ZA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Stephen Bradley Saad
- Headquarters
- Aspen Place, Durban, ZA
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments.
The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand.
It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor.
In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Aspen Pharmacare Holdings Limited, and the rating behind it. APNHY last traded at $8.37, 26.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Aspen Pharmacare Holdings Limited. Starting points for Aspen Pharmacare Holdings Limited: P/E 26.3, EPS $5.97, beta 0.27 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Aspen Pharmacare Holdings Limited. Aspen Pharmacare Holdings Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Aspen Pharmacare Holdings Limited. Trailing twelve-month EPS for Aspen Pharmacare Holdings Limited stands at $5.97. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Aspen Pharmacare Holdings Limited. Aspen Pharmacare Holdings Limited has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Aspen Pharmacare Holdings Limited valued side by side against its closest peers. Aspen Pharmacare Holdings Limited is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Aspen Pharmacare Holdings Limited, and how their positions are changing. At a $3.72B market value, institutional positions materially move Aspen Pharmacare Holdings Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Aspen Pharmacare Holdings Limited executives and directors. Shares of Aspen Pharmacare Holdings Limited have traded between $5.24 and $10.14 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Aspen Pharmacare Holdings Limited. Aspen Pharmacare Holdings Limited is a $3.72B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Aspen Pharmacare Holdings Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Aspen Pharmacare Holdings Limited. Coverage tracks Aspen Pharmacare Holdings Limited within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.